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and Ilmo Leivo11
1Department of Patholosgy, University of Helsinki, Haartmaninkatu 3, PO Box 21, Helsinki FIN-00014, Finland; 2Department of Oral
and Maxillofacial Diseases, University of Helsinki, Haartmaninkatu 8, PO Box 63, Helsinki FI-00014, Finland; 3Institute of Dentistry,
University of Misurata, PO Box 2478, Misurata, Libya; 4Institute for Molecular Medicine Finland (FIMM), University of Helsinki,
Helsinki FIN-00014, Finland; 5Helsinki Institute for Information Technology HIIT and Department of Mathematics and Statistics,
University of Helsinki, Helsinki FIN-00014, Finland; 6Department of Public Health, University of Helsinki, Helsinki FIN-00014,
Finland; 7Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital and University of Helsinki,
Kasarminkatu 11-13, Helsinki FI-00130, Finland; 8Helsinki University Hospital, Helsinki FIN-00014, Finland; 9Research Group of
Cancer Research and Translational Medicine, Medical Faculty, University of Oulu, PO Box 5281, Oulu 90014, Finland; 10Medical
Research Center, Oulu University Hospital, Oulu 90220, Finland and 11Department of Pathology, University of Turku,
Kiinamyllynkatu 10, Turku 20520, Finland
Background: Tumour budding has been reported as a promising prognostic marker in many cancers. This meta-analysis assessed
the prognostic value of tumour budding in oral squamous cell carcinoma (OSCC).
Methods: We searched OvidMedline, PubMed, Scopus and Web of Science for articles that studied tumour budding in OSCC.
We used reporting recommendations for tumour marker (REMARK) criteria to evaluate the quality of studies eligible for meta-
analysis.
Results: A total of 16 studies evaluated the prognostic value of tumour budding in OSCC. The meta-analysis showed that tumour
budding was significantly associated with lymph node metastasis (odds ratio¼ 7.08, 95% CI¼ 1.75–28.73), disease-free survival
(hazard ratio¼ 1.83, 95% CI¼ 1.34–2.50) and overall survival (hazard ratio¼ 1.88, 95% CI¼ 1.25–2.82).
Conclusions: Tumour budding is a simple and reliable prognostic marker for OSCC. Evaluation of tumour budding could facilitate
personalised management of OSCC.
Oral squamous cell carcinoma (OSCC) is the most common
malignancy of the oral cavity and constitutes the majority of head
and neck squamous cell carcinomas. According to a recent report,
B300 000 new cases of oral cancer were diagnosed worldwide in
2012, and with a consequent 145 000 cancer-related deaths (Ferlay
et al, 2015). The incidence of OSCC has increased in many
countries and especially in young people (Muller et al, 2008;
Korvala et al, 2017). In the Western world, the main aetiological
factors for OSCC are tobacco and alcohol consumption. Chewing
of Areca nuts and the use of snuff are the classic risk factors in the
Indian population. The 5-year survival rate of OSCC patients is
relatively low, and especially the patients with recurrence have
poor outcomes. Identifying cases at risk for recurrence remains
challenging.
Many histopathologic prognostic parameters (e.g., tumour
grade, depth of invasion, perineural invasion, lymphovascular
invasion, lymphocytic host response and mitotic activity) are
usually evaluated in haematoxylin- and eosin- (H–E) stained
*Correspondence: Dr A Almangush; E-mail: alhadi.almangush@helsinki.fi or alhadi.almangush@gmail.com
Received 29 September 2017; revised 27 October 2017; accepted 30 October 2017; published online 30 November 2017
r 2018 Cancer Research UK. All rights reserved 0007 – 0920/18
FULL PAPER
Keywords: tumour budding; oral squamous cell carcinoma; prognosis; marker; invasive front; treatment; survival
British Journal of Cancer (2018) 118, 577–586 | doi: 10.1038/bjc.2017.425
www.bjcancer.com | DOI:10.1038/bjc.2017.425 577
sections. Such information is included in pathology reports to aid
in predicting the behaviour of OSCC. This is paramount for
planning of an appropriate and successful management. However,
some of these parameters (e.g., tumour grade and lymphocytic
response) have not been promising prognosticators, especially in
early stage OSCC (Chen et al, 2013; Almangush et al, 2015a).
Moreover, recent research has introduced several biomarkers for
OSCC, but they are not yet eligible to be included in the pathology
report (Soland and Brusevold, 2013; Almangush et al, 2017a). In
addition, such biomarkers require additional staining procedures
which are not routinely used. Therefore, it is important to identify
new powerful prognostic markers that are adaptable to conven-
tional H–E staining.
Tumour budding, defined as the presence of single cancer cell(s)
or cluster(s) of less than five cancer cells at the invasive front (IF),
has been reported in many cancers as a promising prognostic
feature (Kadota et al, 2015; Almangush et al, 2016; Rogers et al,
2016). Tumour budding at the IF (Figure 1) indicates the
dissociation of invasive cancer cells from the main tumour mass.
Several recent studies have evaluated the significance of tumour
budding in OSCC. The aim of the current study was to
systematically review the studies on tumour budding in OSCC
and to present a meta-analysis of the prognostic value of tumour
budding in OSCC. We also discuss the shortcomings in the
published studies and provide recommendations for further
research to standardise the evaluation method of tumour budding
in OSCC.
MATERIALS AND METHODS
Search protocol. OvidMedline, PubMed, Scopus and Web of
Science were searched using the following keywords: (‘oral’ or
‘mouth’ or ‘tongue’ or ‘floor of mouth’ or ‘lip’ or ‘gingiva’ or
‘buccal’ or ‘palate’) and (‘tumour budding’). Our search was limited
to articles in the English language. The end point of the search was
May 2017. To ensure inclusion of all relevant articles, we manually
searched the reference lists of all eligible studies. When searching
and screening the studies, we followed the Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA) (Moher
et al, 2009).
Exclusion criteria. We excluded studies in a language other than
English, studies on animal samples and conference abstracts.
Quality assessment. We used reporting recommendations for
tumour marker prognostic studies (REMARK) guidelines (Altman
et al, 2012) to assess the quality of studies that evaluated the
prognostic value of tumour budding in OSCC. We summarised the
main guidelines in Table 1. Any study that received a score of less
than 6 was not included in our meta-analysis.
Statistical methods. The meta-analysis was performed by the
‘meta’ package (version 4.8-1) in statistical software R (version
3.4.0). For each analysis, we carried out an inverse variance-
weighted fixed-effects analysis. For completeness, a DerSimonian–
Laird random effects analysis (DerSimonian and Laird, 1986) was
also performed. We considered the random effects analysis as our
main result to account for heterogeneity between the studies. In
addition to the meta-analysed effect sizes, our results also included
the estimated proportion of variation in effect sizes due to
heterogeneity (I2) (Higgins and Thompson, 2002) and the
DerSimonian–Laird estimate of the variance of the effect sizes
(t2) (DerSimonian and Laird, 1986). We first conducted meta-
analyses for each survival end point even if tumour stage, oral
subsite or budding cutoff point varied between the studies. To
reduce heterogeneity among the included studies, we then
conducted additional meta-analyses specifically for studies with
early stage cases and for studies from single oral subsite (oral
tongue). We also conducted separate meta-analyses for studies
with a similar cutoff point of tumour budding.
RESULTS
Search results. A total of 63 hits were retrieved from searches of
databases, and 39 hits were excluded as duplicates. There were 22
studies that had evaluated tumour budding in OSCC (Figure 2). Of
these, 16 studies had reported the prognostic value of tumour
budding in OSCC (Table 2). The other six studies had evaluated
tumour budding in OSCC without providing its prognostic value
(Table 3).
Statistical results. A meta-analysis of the prognostic value of
tumour budding for lymph node metastasis, disease-free survival
and overall survival is summarised in Figures 3–5. For each end
Figure 1. Tumour budding, defined as single cancer cell or clusters of less than five cells at the invasive front of oral squamous cell carcinoma
(OSCC). (A) Low magnification ( 4); and (B) high magnification (20) of the area inside the circle.
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point, there was at least one meta-analysis of three high-quality
studies (according to REMARK guidelines; Table 1) that had
reported the necessary statistical values (hazard ratio (HR) or odds
ratio (OR) and confidence interval (CI)). According to our
analyses, there was strong evidence for tumour budding to be
considered as a promising prognostic marker for OSCC.
Our meta-analyses of eligible studies with different budding
cutoff points for risk stratification indicated that high-grade
Table 1. Evaluation criteria that have been used to assess the quality of studies evaluated tumour budding in OSCC (adapted
from REMARK)
Checklist Criteria
Introduction The hypotheses and objectives of the study were clearly explained
Cohort description Retrospective or prospective cohort with a well-defined study population
Medical treatment of the cases was explained
Patient data The basic data such as age, gender, clinical stage and histopathologic grade was provided
Evaluation method Well-described method including the microscopic field/s and the cutoff point. Inter-observer variability was evaluated
Prognostic analysis The survival end point was defined and/or the relationship between the tumour budding and lymph node metastasis was
studied
Statistical analysis Estimated effect (e.g., hazard ratio, relative risk with their confidence interval), which reveal the relationship between tumour
budding and the survival end point/s
The independence of prognostic value was reported by multivariate analysis
Classical prognostic factors The prognostic value of the classical prognostic factors (e.g., stage and grade) were reported
The relationship between tumour budding and classical prognostic factors was reported
Interpretation of the prognostic
value and discussion
Comparison of the current findings with other studies
Strengths and limitations of the current data
Recommendation for further research
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Figure 2. Flow diagram outlining the search strategy and the search results along various steps.
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tumour budding was significantly associated with the presence of
lymph node metastasis (Figure 3A) when compared with low-
grade tumour budding (OR¼ 7.08, 95% CI¼ 1.75–28.73). Subse-
quently, our meta-analysis of studies (Arora et al, 2017; Seki et al,
2017) that used a cutoff point of five buds (Figure 3B) and our
pooled analysis of the other studies (Angadi et al, 2015; Manjula
et al, 2015) that used a cutoff point of 10 buds (Figure 3C) showed
similar odds ratios (OR¼ 7.32, 95% CI¼ 0.49–108.35; and
OR¼ 7.0, 95% CI¼ 2.84–17.29, respectively), while the former
analysis was more heterogeneous.
The pooled analysis for disease-free survival (Figure 4) also
showed that high-grade tumour budding was correlated with
poorer survival (HR¼ 1.83, 95% CI¼ 1.34–2.50). For overall
survival, tumour budding was associated with poor survival when
all stages (Figure 5A) were included (HR¼ 1.88, 95% CI¼ 1.25–
2.82) and also when a meta-analysis of early stage (Figure 5B) cases
only was performed (HR¼ 3.27, 95% CI¼ 1.12–9.55). The pooled
analyses for overall survival of the studies that evaluated tumour
budding in oral tongue cancers using five buds as a cutoff point
also showed similar results (Figure 5C) when advanced stage was
included (HR¼ 2.07, 95% CI¼ 0.88–4.85), as well as when studies
of early stage cases (Figure 5D) were analysed separately
(HR¼ 3.35, 95% CI¼ 0.48–23.62).
We observed potential heterogeneity (I2X66%) between the
studies for two analyses of lymph node metastasis (Figure 3A and
B) and for overall survival meta-analyses (Figure 5), but we could
not assess statistical significance of heterogeneity due to the small
number of studies. Of note, for one meta-analysis of lymph node
metastasis (Figure 3C), as well as for disease-free survival meta-
analysis (Figure 4), we did not observe heterogeneity between the
studies (I2¼ 0).
DISCUSSION
The invasive tumour front of OSCC has been an area of research
interest in recent decades. Cancer cells at the IF behave aggressively
compared with cancer cells in the superficial or central regions of
the main tumour mass (Bryne et al, 1992; Jensen et al, 2015a). In
addition, cancer cells at the IF may undergo epithelial–
mesenchymal transition, which is an important step in progression
of tumour metastasis (Christofori, 2006). Tumour budding that
may be involved in development of metastasis has been reported at
the IF and evaluated in several studies on OSCC (Table 2). Here,
we performed a meta-analysis on the results of such studies. Our
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Abbreviations: AUC¼ area under curve; CI¼ confidence interval; CT¼ chemotherapy; DFS¼disease-free survival; DIA¼digital image analysis; H–E¼haematoxylin and eosin staining;
HR¼hazard ratio; IHC¼ immunohistochemical staining with cytokeratin or pan-cytokeratin.  20¼ refer to  20 objective lens; LNM¼ lymph node metastasis; NA¼ not available; OR¼odds
ratio; OS¼overall survival; %¼percentage of cases with high intensity of tumour buddingl; PFS¼progression free survival; RFS¼ relapse free surviva; RR¼ risk ratio; SCC¼ squamous cell
carcinoma.
aWe conducted the OS from data of our original study Almangush et al, (2015b) for this meta-analysis.
bWe computed a univariate OR (with its 95% CI) estimate for tumour budding from study of Arora et al, 2017.
Notes: Wang et al, (2011) and Xie et al, (2015, 2016) are overlapped. Almangush et al, (2014) and Almangush et al, (2015b) are overlapped. Jensen et al, (2015a) and (Pedersen et al, 2017) are
overlapped. Seki et al, (2016) and Seki et al, (2017) are overlapped. HR, RR, OR and CI in bold are from multivariate analysis.
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meta-analysis shows that tumour budding is a promising
prognostic marker for OSCC.
The importance of tumour budding in cancer prognosis has
been studied widely particularly in colorectal cancer (Rogers et al,
2016; Lugli et al, 2017), where it is recognised as an additional
prognostic marker (Koelzer et al, 2014). In oesophageal cancer
(Almangush et al, 2016), pancreatic cancer (Karamitopoulou,
2012), breast cancer (Gujam et al, 2015) and lung cancer (Kadota
et al, 2014), tumour budding has been reported as a promising
prognostic marker. A significant correlation between high tumour
budding count and the presence of lymph node metastases is one
of the most important findings observed in OSCC (Figure 3) and in
many other cancers (Yamaguchi et al, 2010; Landau et al, 2014;
Salhia et al, 2015; Cappellesso et al, 2017). Such a finding might
indicate that tumour budding is an early step en route to
metastasis. A correlation between tumour budding and occult
lymph node metastasis was reported in early stage OSCC (Xie et al,
2015). As occult metastasis is the most common reason for relapse
and poor prognosis in early stage cases, it is of great importance to
validate this correlation in other large multicentre cohorts.
Simplicity, reproducibility and low cost are important char-
acteristics when considering a new marker for clinical application.
The published studies in OSCC and in other cancers repeatedly
reported these advantages for tumour budding (Wang et al, 2011;
Graham et al, 2015; Almangush et al, 2015b). Another advantage
of the studies of tumour budding in OSCC is that their results are
consistent with those from the first study that evaluated budding in
OSCC (Wang et al, 2011). Conversely, controversial findings were
reported for the prognostic biomarkers identified for OSCC
(Soland and Brusevold, 2013; Almangush et al, 2017a).
When considering a new prognostic marker for clinical
application, the marker should also have a significant prognostic
value independent from classical markers. Interestingly, for tumour
budding, most of the studies that provided multivariate analysis
(Wang et al, 2011; Angadi et al, 2015; Almangush et al, 2015b; Seki
et al, 2016; Hori et al, 2017; Pedersen et al, 2017) reported that
tumour budding has a superior prognostic value compared to other
classical markers such as TNM stage, depth of invasion or WHO
tumour grade. However, in one study, (Manjula et al, 2015),
tumour thickness (5-mm cutoff point) showed superior prognostic
value compared with tumour budding, and the same was observed
for depth of invasion in the study by Arora et al. (2017). In another
study (Jensen et al, 2015a), advanced stage was associated with a
poorer prognosis than in cases with high-grade budding. Of note,
in the latter two studies (Jensen et al, 2015a; Arora et al, 2017)
tumour budding was also reported as an independent prognostic
marker in multivariate analysis. Therefore, multivariate analysis of
published studies indicates that high-intensity tumour budding,
either independently or in addition to the advanced stage, deeply
invaded tumour or both, is associated with poor prognosis of
OSCC. Only in the study by Manjula et al. (2015), tumour budding
was not a prognostic marker in multivariate analysis. However,
Manjula et al. used a 10-bud cutoff point to stratify cases into risk
scores, and it is possible that some cases with Xfive buds were
included in the low-grade budding group, which subsequently
reduced the prognostic value of tumour budding in this cohort.
Different methods have been introduced for the evaluation of
tumour budding (Koelzer et al, 2014). However, a traditional
method was widely used in the studies on OSCC. In this method,
the IF is scanned under low magnification ( 4), and the field with
the highest budding number is counted under high magnification
( 20) and used for the score (Wang et al, 2011). The evaluation of
intra-tumoural budding was not reported in OSCC. Of note, intra-
tumoural budding was shown as a valid method in colorectal
cancer (Lugli et al, 2011). In only a few studies, evaluation of the
prognostic value of tumour budding at the IF was carried out in
biopsy specimens of OSCC (Seki et al, 2016, 2017; Almangush et al,
2017b). However, the IF area might not be included in a biopsy
specimen. In such cases, another form of tumour budding, the
intra-tumoural budding (i.e., tumour budding between tumour
islands) might be more applicable. The latter approach may be of
great importance from a clinical point of view for treatment
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planning of OSCC, and should be further evaluated. In addition,
intraoperative evaluation of tumour budding (i.e., using fresh-
frozen sections) should also be considered in future studies.
Diverse cutoff points were suggested for stratification of cases
into low-grade and high-grade tumour budding (Table 2). In the
present studies on OSCC, five-bud cutoff point was the most
commonly used (low grade o5 vs high grade X5). We conducted
meta-analysis for studies that used different cutoff points
(Figure 3A), and then, we conducted separate meta-analyses for
studies that used a five-bud cutoff point (Figure 3B) and for studies
that used a 10-bud cutoff point (Figure 3C). Interestingly, these
meta-analyses show that tumour budding is a useful prognostic
marker for OSCC cases. As the risk of poor prognosis begins at the
presence of five buds, we suggest considering both five-bud and 10-
bud cutoff points in further studies to determine which one of
these cutoff points is more predictive of poor prognosis and should
therefore be used in clinical practice.
Most studies evaluated tumour budding using H–E staining.
Interestingly, a recent study on OSCC concluded that evaluation of
tumour budding by immunohistochemistry with pan-cytokeratin
antibodies (clones AE1/AE3) showed a better reproducibility of
results than those with H–E staining (Leao et al, 2017). However,
standardisation of the evaluation method and cutoff point is still
necessary. A recent international consensus conference on tumour
budding (Lugli et al, 2017) made several statements (including
definition, evaluation method and others) for reporting tumour
budding in colorectal cancer. Such statements are still necessary to
allow inclusion of tumour budding in a pathology report for OSCC
cases.
The combination of squamous cell carcinoma (SCC) from
different subsites of the oral cavity was a common disadvantage
among the studies that evaluated tumour budding in OSCC.
Therefore, we recommend a separate analysis for each subsite
when reporting tumour budding in future studies. Despite a small
number of studies available, we conducted a meta-analysis for
overall survival of studies that evaluated tumour budding in oral
tongue SCC (Figure 5C and D), which is the most common SCC of
the oral cavity. The results of this meta-analysis suggest, although
without strong statistical evidence, that cases of oral tongue cancer
with a high budding index have a poorer overall survival. This is
consistent with the other meta-analyses where the subsites were
mixed. Another combination that was also common among the
included studies was mixing of early stage and late-stage cancers in
the same analysis. We conducted a meta-analysis for the two
studies that included only early stage cancers (Figure 5D), and the
result suggests that tumour budding in such early stage cases has a
prognostic value, but given the wide confidence intervals, this
result lacks strong statistical evidence and requires further studies
for validation.
Tumour budding in OSCC has also been evaluated using digital
pathology (Jensen et al, 2015a; Pedersen et al, 2017). Digital image
analysis has been used increasingly in recent research and it has
shown better accuracy and reproducibility compared with the
conventional method as it allows truly quantitative scores (Riber-
Hansen et al, 2012). Moreover, it will be easier to standardise the
scoring method using digital image analysis (Pedersen et al, 2017).
Therefore, digital image analysis of tumour budding in OSCC
should be used to validate results in large cohorts.
Few studies have examined the biological background of tumour
budding in OSCC. Immunohistochemical analysis showed that
tumour budding is associated with reduced expression of
E-cadherin and overexpression of vimentin (Wang et al, 2011).
Regarding interactions with the surrounding stroma, high-grade
budding was associated with a higher density of stromal
myofibroblasts and higher expression of laminin-5 gamma 2 chain
(Marangon Junior et al, 2014). In genetic profiling, decreased
expression of miR-200a, miR-200b and miR-200c was reported in
cancer cells of tumour budding (Jensen et al, 2015a). However,
molecular analyses in other cancers have provided more details
about the genetic background of tumour budding (Zlobec and
Lugli, 2010; Galvan et al, 2015; Bradley et al, 2016; Miyake et al,
2017), and similar analyses in OSCC are still necessary to better
understand this phenomenon.
The main limitation of the current meta-analyses is the small
number of the original studies. Accordingly, it was difficult to
statistically evaluate the heterogeneity between the studies. To
avoid bias due to any potential heterogeneity, we focused on a
random effects model that is known as an effective method to
combine heterogeneous studies (Guolo and Varin, 2017). In
addition, for each meta-analysis (Figures 3–5), we also reported
results of a fixed effect model and they were consistent with a
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Figure 3. Forest plots for the pooled analyses of the studies evaluated
the prognostic value of tumour budding in assessing lymph node
metastasis of OSCC. (A) All eligible studies. (B) Studies used five-bud














I2 = 0%, 2 = 0
Figure 4. Pooled analysis for disease-free survival.
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three different end points (metastasis, overall survival and disease-
free survival), and our results regarding the common effect of
tumour budding as a negative prognostic marker are valid based on
meta-analyses of these different end points. Of note, this effect is
also consistent across published studies. Inclusion of different
subsites of the oral cavity or mixing of different stages in analysis of
the same cohort was another limitation, as mentioned above. The
absence of prospective studies was also noted.
Despite these shortcomings, there is sufficient evidence to
suggest that OSCCs with high-grade tumour budding are at high
risk of poor prognosis. This evidence was prominent and validated
in many studies. Similar evidence has also accumulated on the
prognostic value of tumour budding in other cancers (Almangush
et al, 2016; Rogers et al, 2016; Lugli et al, 2017). To the best of our
knowledge, this is the first meta-analysis on the prognostic value of
tumour budding in OSCC. We conclude that tumour budding has
a prominent prognostic power for OSCC even at early stages of the
disease. Future research on OSCC should compare the different
evaluation methods with the goal of standardising the assessment
method for pathology reports. In addition, understanding the
genetic background of tumour budding may facilitate identification
of treatment targets in OSCC.
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(Antti A Mäkitie and Tuula Salo), the Sigrid Juselius Foundation
(Tuula Salo), the Finnish Cancer Society (Tuula Salo) and the
Maritza and Reino Salonen Foundation (Ilmo Leivo).
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Almangush A, Bello IO, Coletta RD, Makitie AA, Makinen LK, Kauppila JH,
Pukkila M, Hagstrom J, Laranne J, Soini Y, Kosma VM, Koivunen P,
Kelner N, Kowalski LP, Grenman R, Leivo I, Laara E, Salo T (2015a) For
early-stage oral tongue cancer, depth of invasion and worst pattern of
invasion are the strongest pathological predictors for locoregional
recurrence and mortality. Virchows Arch 467(1): 39–46.
Almangush A, Bello IO, Keski-Santti H, Makinen LK, Kauppila JH,
Pukkila M, Hagstrom J, Laranne J, Tommola S, Nieminen O, Soini Y,
Kosma VM, Koivunen P, Grenman R, Leivo I, Salo T (2014) Depth of
invasion, tumor budding, and worst pattern of invasion: prognostic
indicators in early-stage oral tongue cancer. Head Neck 36(6): 811–818.
Almangush A, Coletta RD, Bello IO, Bitu C, Keski-Santti H, Makinen LK,
Kauppila JH, Pukkila M, Hagstrom J, Laranne J, Tommola S, Soini Y,
Kosma VM, Koivunen P, Kowalski LP, Nieminen P, Grenman R, Leivo I,
Salo T (2015b) A simple novel prognostic model for early stage oral
tongue cancer. Int J Oral Maxillofac Surg 44(2): 143–150.
Almangush A, Heikkinen I, Makitie AA, Coletta RD, Laara E, Leivo I, Salo T
(2017a) Prognostic biomarkers for oral tongue squamous cell carcinoma: a
systematic review and meta-analysis. Br J Cancer 117(6): 856–866.
Almangush A, Karhunen M, Hautaniemi S, Salo T, Leivo I (2016) Prognostic
value of tumour budding in oesophageal cancer: a meta-analysis.
Histopathology 68(2): 173–182.
Almangush A, Leivo I, Siponen M, Sundquist E, Mroueh R, Makitie AA,
Soini Y, Haglund C, Nieminen P, Salo T (2017b) Evaluation of the
budding and depth of invasion (BD) model in oral tongue cancer biopsies.
Virchows Arch; epub ahead of print 2 August 2017; doi:10.1007/s00428-
017-2212-1.
Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting
recommendations for tumor marker prognostic studies (REMARK):
explanation and elaboration. BMC Med 10: 51.
Angadi PV, Patil PV, Hallikeri K, Mallapur MD, Hallikerimath S, Kale AD
(2015) Tumor budding is an independent prognostic factor for prediction
of lymph node metastasis in oral squamous cell carcinoma. Int J Surg
Pathol 23(2): 102–110.
Arora A, Husain N, Bansal A, Neyaz A, Jaiswal R, Jain K, Chaturvedi A,
Anand N, Malhotra K, Shukla S (2017) Development of a new outcome
prediction model in early-stage squamous cell carcinoma of the oral cavity
based on histopathologic parameters with multivariate analysis: the aditi-
nuzhat lymph-node prediction score (ANLPS) system. Am J Surg Pathol
41(7): 950–960.
Attramadal CG, Kumar S, Boysen ME, Dhakal HP, Nesland JM, Bryne M
(2015) Tumor budding, EMT and cancer stem cells in T1-2/N0 oral
squamous cell carcinomas. Anticancer Res 35(11): 6111–6120.
Boxberg M, Jesinghaus M, Dorfner C, Mogler C, Drecoll E, Warth A,
Steiger K, Bollwein C, Meyer P, Wolff KD, Kolk A, Weichert W (2017)
Tumor budding activity and cell nest size determine patient outcome in
oral squamous cell carcinoma: Proposal for an adjusted grading system.
Histopathology 70(7): 1125–1137.
Bradley CA, Dunne PD, Bingham V, McQuaid S, Khawaja H, Craig S, James J,
Moore WL, McArt DG, Lawler M, Dasgupta S, Johnston PG, Van























0.2 10.5 2 5
0.2 10.5 2 5
0.1 10.5 2 10


































I2 = 86%, 2 = 1.728
Figure 5. Pooled analyses for overall survival. (A) All stages of OSCC.
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